ERS Genomics Ltd
ERS Genomics is a global leader in CRISPR/Cas9 gene editing technology licensing, providing broad access to foundational CRISPR/Cas9 intellectual property. Founded on the Nobel Prize-winning discoveries of Emmanuelle Charpentier and Jennifer Doudna, ERS licenses over 85 patents worldwide, supporting innovation across industries such as biotech, pharma, agriculture, and synthetic biology. The company aims to democratize access to CRISPR technology, enabling researchers and companies to develop life-changing treatments and technologies responsibly and efficiently.
Industries
Nr. of Employees
small (1-50)
ERS Genomics Ltd
Wework, 5 Harcourt Road, Dublin 2, D02 FW64
Products
Start‑up Guide (downloadable)
A downloadable guide aimed at startups describing licensing options and practical steps for accessing CRISPR/Cas9 intellectual property.
Advancing the Frontiers of Biotherapeutics (downloadable)
A technical/downloadable brief on applications of CRISPR/Cas9 in therapeutic protein production and biotherapeutics.
The facts about CRISPR/Cas9 Licensing (downloadable)
A short downloadable briefing that addresses common questions and misperceptions about licensing CRISPR/Cas9.
Start‑up Guide (downloadable)
A downloadable guide aimed at startups describing licensing options and practical steps for accessing CRISPR/Cas9 intellectual property.
Advancing the Frontiers of Biotherapeutics (downloadable)
A technical/downloadable brief on applications of CRISPR/Cas9 in therapeutic protein production and biotherapeutics.
The facts about CRISPR/Cas9 Licensing (downloadable)
A short downloadable briefing that addresses common questions and misperceptions about licensing CRISPR/Cas9.
Services
Negotiate and grant licences that provide freedom-to-operate under a foundational CRISPR/Cas9 patent portfolio for internal research and many commercial applications outside direct human gene and cell therapy.
A streamlined licensing pathway designed for small organisations and startups to obtain a non-exclusive internal-research licence with simplified eligibility criteria and faster onboarding.
Advisory support on the patent landscape, ongoing monitoring of legal developments, and structuring licence terms to address freedom-to-operate risks.
Negotiate and execute licence agreements and collaboration terms with service providers, CROs and industry partners to enable CRISPR-enabled programs and preclinical tool development.
Negotiate and grant licences that provide freedom-to-operate under a foundational CRISPR/Cas9 patent portfolio for internal research and many commercial applications outside direct human gene and cell therapy.
A streamlined licensing pathway designed for small organisations and startups to obtain a non-exclusive internal-research licence with simplified eligibility criteria and faster onboarding.
Advisory support on the patent landscape, ongoing monitoring of legal developments, and structuring licence terms to address freedom-to-operate risks.
Negotiate and execute licence agreements and collaboration terms with service providers, CROs and industry partners to enable CRISPR-enabled programs and preclinical tool development.
Expertise Areas
- Intellectual property licensing and management (gene editing IP)
- CRISPR/Cas9 platform applications
- Preclinical model development (engineered cell lines, organoids, PDX)
- Synthetic biology and industrial bioproduction
Key Technologies
- CRISPR/Cas9 gene editing
- Base editing
- Prime editing
- CRISPRa/CRISPRi (CRISPR-based gene regulation)
News & Updates
Reflection on the progress and impact of CRISPR technology in 2024, including milestones like FDA approval of CRISPR therapies.
The U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute, leading to a reconsideration of patent priority.
Discussion on the convergence of AI and CRISPR technologies to accelerate gene editing and biotechnological innovations.
A case study on how Bioneer is utilizing CRISPR technology licensed from ERS Genomics.
A message from CEO John E. Milad reflecting on the company's achievements and future directions.
Over 85 issued patents in over 80 countries
ERS Genomics holds a foundational collection of CRISPR/Cas9 patents, supporting global innovation.
Reflection on the progress and impact of CRISPR technology in 2024, including milestones like FDA approval of CRISPR therapies.
The U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute, leading to a reconsideration of patent priority.
Discussion on the convergence of AI and CRISPR technologies to accelerate gene editing and biotechnological innovations.
A case study on how Bioneer is utilizing CRISPR technology licensed from ERS Genomics.
A message from CEO John E. Milad reflecting on the company's achievements and future directions.
Over 85 issued patents in over 80 countries
ERS Genomics holds a foundational collection of CRISPR/Cas9 patents, supporting global innovation.